Corcym reports first U.S. implantation of next-gen sutureless aortic valve

Corcym has completed the first U.S. implantation of its next-generation Perceval Plus Lancelot sutureless aortic valve, the company told MassDevice today.

The Perceval Plus Lancelot valve introduces a next-generation manufacturing process intended to enhance valve performance and durability. It features precision laser-cut bovine pericardial leaflets designed to enhance hemodynamics and improve the accuracy and consistency of the valve’s structure.

The new Lancelot technology uses a CO2 infrared laser to cut through bovine pericardium and pre-sets the sutures. The technology is designed to improve the reproducibility of the sewing process. Lancelot integrates a zero-pressure shaping process engineered to preserve tissue integrity and boost the mechanical properties and stability of the tissue, which Corcym expects to contribute to consistent reproducibility and enhanced durability of the valve.

“At Corcym, innovation begins and ends with the patient,” said Corcym CEO Christian Mazzi. “The first U.S. implantation of our Perceval Plus Lancelot valve reflects our commitment to advancing surgical technologies that support cardiac surgeons and improve outcomes for patients with structural heart disease.”

Listen to our DeviceTalks Weekly podcast with Corcym CEO Christian Mazzi to hear more about the company’s quest to transform surgical heart valve replacement.

The first U.S. implant using the new valve technology was performed in September 2025, and the patient has recovered and returned to daily activities, Corcym said.

The valve expands on Corcym’s established Perceval platform and the company’s overall surgical heart valve solutions portfolio.

Corcym’s Perceval Plus valves were designed around a superelastic nitinol stent that self-expands in place, eliminating the need to knot sutures and ensuring optimal valve sealing. The stent reduces the stress transferred to the leaflets and allows the valve to follow the physiological movement of the aortic root during the cardiac cycle, mimicking the native valve.

Perceval Plus valves made with the new Lancelot technology, like the one the patient received, include the precision laser-cut bovine leaflets.

“The introduction of next-generation sutureless valve technology represents an important step forward in surgical options for patients with aortic valve disease,” said Chief of Cardiac Surgery at CHI Health and proctor for the procedure, Dr. Robert Gallegos. “Innovations like this can help surgeons perform procedures efficiently while supporting strong valve performance and long-term outcomes for patients.”